Reconstituted histone methyltransferase complex and methods of identifying modulators thereof

• US 7,563,589 B2
• Filed: 05/27/2005
• Issued: 07/21/2009
• Est. Priority Date: 06/01/2004
• Status: Expired due to Fees

• Current Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Original Assignee: University of North Carolina At Chapel Hill (University of North Carolina System)
• Inventors: Cao, Ru, Zhang, Yi
• Primary Examiner(s): Nashed; Nashaat T
• Assistant Examiner(s): CHOWDHURY, IQBAL HOSSAIN
• Application Number:
  US11/140,659
• Publication Number:
  US 20050266473A1
• Time in Patent Office: 1,516 Days
• Field of Search: 435/6, 435/193, 435/348, 435/69.1, 435/320.1, 435/15, 536/23.2
• US Class Current: 435/15
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C07K 2319/20 containing a tag with affinity for a non-protein ligand
• CPC Class Codes: C12N 2799/026 where the vector is derived from a baculovirus
• CPC Class Codes: C12N 9/1007 Methyltransferases (general) (2.1.1.)
• CPC Class Codes: C12Y 201/01043 Histone-lysine N-methyltransferase (2.1.1.43)
• CPC Class Codes: G01N 2333/91011 Methyltransferases (general) (2.1.1.)

Abstract

The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

Claims

1. A method of identifying a compound that inhibits the histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27) of a reconstituted complex comprising mammalian Embryonic Ectoderm Development (FED), Enhancer of Zeste Homolog 2 (EZH2), and Suppressor of Zeste 12 (SUZ12), wherein the reconstituted complex has H3-K27 HMTase activity, the method comprising:

contacting the reconstituted complex with a histone substrate in the presence of a test compound; and

detecting the level of H3-K27 methylation under conditions sufficient to provide H3-K27 methylation, wherein a reduction in H3-K27 methylation as compared with the level of H3-K27 methylation in the absence of the test compound indicates that the test compound is an inhibitor of the H3-K27 HMTase activity of the reconstituted complex.

2. The method of claim 1, wherein the reconstituted complex further comprises mammalian RbAp48, AEBP2 or both.

3. The method of claim 1, wherein the histone substrate is a core histone, a histone octamer, a mononucleosome, a dinucleosome or an oligonucleosome.

4. The method of claim 1, wherein the histone substrate is a dinucleosome.

5. The method of claim 1, wherein the method is a cell-based method.

6. The method of claim 1, wherein the method is a cell-free method.

9. The method of claim 1, wherein at least one of the proteins in the complex is a fusion protein comprising a purification tag.

7. A method of identifying a candidate compound for treating cancer, comprising:

contacting a reconstituted complex comprising mammalian Embryonic Ectoderm Development (EED), Enhancer of Zeste Homolog 2 (EZH2) and Suppressor of Zeste 12 (SUZ12) with a histone substrate in the presence of a test compound;

wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27); and

detecting the level of histone methylation of H3-K27 under conditions sufficient to provide H3-K27methylation, wherein a reduction in H3-K27 methylation as compared with the level of H3-K27 methylation in the absence of the test compound indicates that the test compound is a candidate compound for the treatment of cancer.

8. The method of claim 7, wherein the reconstituted complex further comprises mammalian RbAp48, AEBP2 or both.

10. The method of claim 7, wherein at least one of the proteins in the complex is a fusion protein comprising a purification tag.

11. The method of claim 7, wherein the histone substrate is a core histone, a histone octamer, a mononucleosome, a dinucleosome or an oligonucleosome.

12. The method of claim 7, wherein the method is a cell-based method.

13. The method of claim 7, wherein the method is a cell-free method.

14. A method of identifying a compound that inhibits the histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27) of a reconstituted complex comprising human Embryonic Ectoderm Development (EED), Enhancer of Zeste Homolog 2 (EZH2), and Suppressor of Zeste 12 (SUZ12), wherein the reconstituted complex has H3-K27 HMTase activity, the method comprising:

contacting the reconstituted complex with a histone substrate in the presence of a test compound; and

detecting the level of H3-K27 methylation under conditions sufficient to provide H3-K27 methylation, wherein a reduction in H3-K27 methylation as compared with the level of H3-K27 methylation in the absence of the test compound indicates that the test compound is an inhibitor of the H3-K27 HMTase activity of the reconstituted complex.

15. A method of identifying a candidate compound for treating cancer, comprising:

contacting a reconstituted complex comprising human Embryonic Ectoderm Development (EED), Enhancer of Zeste Homolog 2 (EZH2) and Suppressor of Zeste 12 (SUZ12) with a histone substrate in the presence of a test compound;

wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27); and

detecting the level of histone methylation of H3-K27 under conditions sufficient to provide H3-K27 methylation, wherein a reduction in H3-K27 methylation as compared with the level of H3-K27 methylation in the absence of the test compound indicates that the test compound is a candidate compound for the treatment of cancer.